Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement.
ALCL
ALK negative
DUSP22 rearrangement
Myxoid change
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
25
05
2022
accepted:
21
07
2022
revised:
05
07
2022
pubmed:
26
7
2022
medline:
15
12
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Systemic anaplastic lymphoma kinase-negative (ALK-) anaplastic large cell lymphoma (ALCL) comprises a genomically heterogeneous disease that is considered a distinct entity by the 2016 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Other than lymph nodes, systemic ALK- ALCL may affect extranodal tissues, sites where the inflammatory background may be especially prominent. In this scenario, myxoid change is exceptional in systemic ALK- ALCL. We describe a rare case of systemic ALK- ALCL with distinctive myxoid changes, carrying specific chromosomal aberrations that affect the clinical outcome. Careful morphological, immunohistochemical, and molecular workup is mandatory because a myxoid background should not be a reason to ignore the possibility of a lymphoma. Finally, extensive correlation with staging and the detection of prognostic biomarkers such as DUSP22 and TP63 rearrangements are essential for the diagnosis and prediction of clinical outcome in ALK- ALCL.
Identifiants
pubmed: 35879438
doi: 10.1007/s00428-022-03386-5
pii: 10.1007/s00428-022-03386-5
doi:
Substances chimiques
DUSP22 protein, human
EC 3.1.3.48
Dual-Specificity Phosphatases
EC 3.1.3.48
Mitogen-Activated Protein Kinase Phosphatases
EC 3.1.3.16
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-979Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H et al (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66(4):848–858
doi: 10.1182/blood.V66.4.848.848
Chan JK, Buchanan R, Fletcher CD (1990) Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol 14(10):983–988
doi: 10.1097/00000478-199010000-00013
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390
doi: 10.1182/blood-2016-01-643569
Pina-Oviedo S, Ortiz-Hidalgo C, Carballo-Zarate AA, Zarate-Osorno A (2021) ALK-negative anaplastic large cell lymphoma: current concepts and molecular pathogenesis of a heterogeneous group of large T-cell lymphomas. Cancers (Basel) 13(18):4667
doi: 10.3390/cancers13184667
Gable AD, Clark SH, Magro CM (2012) Myxoid variant of anaplastic large cell lymphoma involving the skin: a case report. J Cutan Pathol 39(8):787–790
doi: 10.1111/j.1600-0560.2012.01911.x
Papalas JA, Van Mater D, Wang E (2010) Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young. Am J Dermatopathol 32(8):821–827
doi: 10.1097/DAD.0b013e3181d81dc3
Fratoni S, Niscola P, Zhao XF, Larocca LM, Capalbo A, Fabbretti M, Bernardini L, Abruzzese E (2020) ALK-negative anaplastic large cell lymphoma with “Hodgkin-like” cytomorphology and nuclear expression of PAX5. Pathol Res Pract 216(2):152724
doi: 10.1016/j.prp.2019.152724
Khanlari M, Tang G, Hao S, Gong Y, Li S, Miranda RN, Lin P, Iyer S, Yin CC, Xie W, Vega F, Medeiros LJ, Xu J (2021) Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. Br J Haematol 192(1):e17–e21
doi: 10.1111/bjh.17169
Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L et al (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473–1480
doi: 10.1182/blood-2014-04-571091
Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, Sattler CA, Boddicker RL, Bennani NN, Nørgaard P, Møller MB, Steiniche T, d’Amore F, Feldman AL (2017) DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood 130(4):554–557. https://doi.org/10.1182/blood-2016-12-755496.]
doi: 10.1182/blood-2016-12-755496.]
Karube K, Feldman AL (2020) “Double-hit” of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative. Blood 135(9):700
doi: 10.1182/blood.2019004164
Klairmont MM, Ward N (2022) Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes. Leuk Lymphoma 63(2):506–508
doi: 10.1080/10428194.2021.1984457
Mélard P, Idrissi Y, Andrique L, Poglio S, Prochazkova-Carlotti M, Berhouet S, Boucher C, Laharanne E, Chevret E, Pham-Ledard A, De Souza Góes AC, Guyonnet-Duperat V, Bibeyran A, Moreau-Gaudry F, Vergier B, Beylot-Barry M, Merlio JP, Cappellen D (2016) Molecular alterations and tumor suppressive function of the DUSP22 (dual specificity phosphatase 22) gene in peripheral T-cell lymphoma subtypes. Oncotarget 7(42):68734–68748
doi: 10.18632/oncotarget.11930